Korean Journal of Radiology

  • 제12권2호
  • /
  • Pages.176-186
  • /
  • 2011
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Concurrent Chemotherapy and Pulsed High-Intensity Focused Ultrasound Therapy for the Treatment of Unresectable Pancreatic Cancer: Initial Experiences

  • Lee, Jae-Young (Department of Radiology and the Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Choi, Byung-Ihn (Department of Radiology and the Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Ryu, Ji-Kon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Yong-Tae (Department of Internal Medicine, Seoul National University Hospital) ;
  • Hwang, Joo-Ha (Department of Medicine, University of Washington Medical Center) ;
  • Kim, Se-Hyung (Department of Radiology and the Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Han, Joon-Koo (Department of Radiology and the Institute of Radiation Medicine, Seoul National University Hospital)
  • 발행 : 2011.04.01
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This study was performed to evaluate the potential clinical value of concurrent chemotherapy and pulsed high intensity focused ultrasound (HIFU) therapy (CCHT), as well as the safety of pulsed HIFU, for the treatment of unresectable pancreatic cancer. Materials and Methods: Twelve patients were treated with HIFU from October 2008 to May 2010, and three of them underwent CCHT as the main treatment (the CCHT group). The overall survival (OS), the time to tumor progression (TTP), the complications and the current performance status in the CCHT and non-CCHT groups were analyzed. Nine patients in the non-CCHT group were evaluated to determine why CCHT could not be performed more than twice. Results: The OS of the three patients in the CCHT group was 26.0, 21.6 and 10.8 months, respectively, from the time of diagnosis. Two of them were alive at the time of preparing this manuscript with an excellent performance status, and one of them underwent a surgical resection one year after the initiation of CCHT. The TTP of the three patients in the CCHT group was 13.4, 11.5 and 9.9 months, respectively. The median OS and TTP of the non-CCHT group were 10.3 months and 4.4 months, respectively. The main reasons why the nine patients of the non-CCHT group failed to undergo CCHT more than twice were as follows: pancreatitis (n = 1), intolerance of the pain during treatment (n = 4), palliative use of HIFU for pain relief (n = 1) and a poor physical condition due to disease progression (n = 3). No major complications were encountered except one case of pancreatitis. Conclusion: This study shows that CCHT is a potentially effective and safe modality for the treatment of unresectable pancreatic cancer.

키워드

참고문헌

  1. Kim YS, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused ultrasound therapy: an overview for radiologists. Korean J Radiol 2008;9:291-302 https://doi.org/10.3348/kjr.2008.9.4.291
  2. Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, et al. Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology 2005;236:1034-1040 https://doi.org/10.1148/radiol.2362041105
  3. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513- 5518 https://doi.org/10.1200/JCO.2009.24.2446
  4. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-2217 https://doi.org/10.1200/JCO.2006.09.0886
  5. Park JK, Ryu JK, Lee JK, Yoon WJ, Lee SH, Kim YT, et al. Gemcitabine chemotherapy versus 5-fluorouracilbased concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 2006;33:397-402 https://doi.org/10.1097/01.mpa.0000236725.26672.be
  6. Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, et al. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007;60:489-494 https://doi.org/10.1007/s00280-006-0390-7
  7. Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, Zhu H, et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol 2001;27:1099-1106 https://doi.org/10.1016/S0301-5629(01)00389-1
  8. Li JJ, Gu MF, Luo GY, Liu LZ, Zhang R, Xu GL. Complications of high intensity focused ultrasound for patients with hepatocellular carcinoma. Technol Cancer Res Treat 2009;8:217-224 https://doi.org/10.1177/153303460900800306
  9. Li JJ, Xu GL, Gu MF, Luo GY, Rong Z, Wu PH, et al. Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors. World J Gastroenterol 2007;13:2747-2751 https://doi.org/10.3748/wjg.v13.i19.2747
  10. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007;13:2722- 2727 https://doi.org/10.1158/1078-0432.CCR-06-2443
  11. Poff JA, Allen CT, Traughber B, Colunga A, Xie J, Chen Z, et al. Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 2008;248:485-491 https://doi.org/10.1148/radiol.2482071674
  12. Wang RS, Liu LX, Gu YH, Lin QF, Guo RH, Shu YQ. The effect of endostatin and gemcitabine combined with HIFU on the animal xenograft model of human pancreatic cancer. Biomed Pharmacother 2010;64:309-312 https://doi.org/10.1016/j.biopha.2009.09.011
  13. Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs 2010;21:447-452 https://doi.org/10.1097/CAD.0b013e32833641a7
  14. Xiong LL, Hwang JH, Huang XB, Yao SS, He CJ, Ge XH, et al. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP 2009;10:123-129
  15. Hwang JH, Wang YN, Warren C, Upton MP, Starr F, Zhou Y, et al. Preclinical in vivo evaluation of an extracorporeal HIFU device for ablation of pancreatic tumors. Ultrasound Med Biol 2009;35:967-975 https://doi.org/10.1016/j.ultrasmedbio.2008.12.006
  16. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758- 765 https://doi.org/10.1007/s10434-001-0758-1
  17. Wolff RA. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas: great logic, grim reality. Ann Surg Oncol 2001;8:747-748 https://doi.org/10.1007/s10434-001-0747-4
  18. Paparel P, Chapelon JY, Bissery A, Chesnais S, Curiel L, Gelet A. Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study. Prostate Cancer Prostatic Dis 2008;11:181-186 https://doi.org/10.1038/sj.pcan.4501005

피인용 문헌

  1. Complete Responses after Hyperthermic Ablation by Ultrasound Guided High Intensity Focused Ultrasound Plus Systemic Chemotherapy for Locally Advanced Pancreatic Cancer vol.2013, pp.None, 2011, https://doi.org/10.1155/2013/586769
  2. New clinical application of high-intensity focused ultrasound: local control of synovial sarcoma vol.11, pp.None, 2011, https://doi.org/10.1186/1477-7819-11-265
  3. Advances of high intensity focused ultrasound (HIFU) for pancreatic cancer vol.29, pp.7, 2011, https://doi.org/10.3109/02656736.2013.837199
  4. High-Intensity Focused Ultrasound Treatment for Advanced Pancreatic Cancer vol.2014, pp.None, 2014, https://doi.org/10.1155/2014/205325
  5. High-intensity Focused Ultrasound Ablation of Soft-tissue Tumors and Assessment of Treatment Response with Multiparametric Magnetic Resonance Imaging: Preliminary Study Using Rabbit VX2 Tumor Model vol.22, pp.2, 2011, https://doi.org/10.1016/j.jmu.2014.02.006
  6. Systematic review of minimally invasive ablation treatment for locally advanced pancreatic cancer vol.119, pp.7, 2014, https://doi.org/10.1007/s11547-014-0417-9
  7. Portable high-intensity focused ultrasound system with 3D electronic steering, real-time cavitation monitoring, and 3D image reconstruction algorithms: a preclinical study in pigs vol.33, pp.3, 2014, https://doi.org/10.14366/usg.14008
  8. Dynamic contrast-enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic canc vol.24, pp.9, 2011, https://doi.org/10.1007/s00330-014-3260-4
  9. High intensity focused ultrasound: A noninvasive therapy for locally advanced pancreatic cancer vol.20, pp.44, 2011, https://doi.org/10.3748/wjg.v20.i44.16480
  10. Clinical Observation of High Intensity Focused Ultrasound (HIFU) Ablation Combined with Qingyihuaji Formula for Salvage Treatment for Advanced Pancreatic Cancer Patients Failed to Systemic Chemotherap vol.4, pp.1, 2011, https://doi.org/10.12677/acrpo.2015.41001
  11. Ultrasound Guided High Intensity Focused Ultrasound for malignant tumors: The Spanish experience of survival advantage in stage III and IV pancreatic cancer vol.27, pp.None, 2011, https://doi.org/10.1016/j.ultsonch.2015.05.026
  12. Therapeutic Effects of Microbubbles Added to Combined High-Intensity Focused Ultrasound and Chemotherapy in a Pancreatic Cancer Xenograft Model vol.17, pp.5, 2011, https://doi.org/10.3348/kjr.2016.17.5.779
  13. Contrast-enhanced ultrasound evaluation of pancreatic cancer xenografts in nude mice after irradiation with sub-threshold focused ultrasound for tumor ablation vol.8, pp.23, 2017, https://doi.org/10.18632/oncotarget.16621
  14. Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy vol.36, pp.6, 2011, https://doi.org/10.1080/08830185.2017.1363199
  15. Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies vol.35, pp.1, 2011, https://doi.org/10.1080/02656736.2018.1506165
  16. A portable high-intensity focused ultrasound system for the pancreas with 3D electronic steering: a preclinical study in a swine model vol.37, pp.4, 2018, https://doi.org/10.14366/usg.17048
  17. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients vol.12, pp.None, 2011, https://doi.org/10.2147/ott.s185424
  18. High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells vol.12, pp.None, 2011, https://doi.org/10.2147/ott.s185953
  19. High-intensity focused ultrasound for treatment of recurrent uterine leiomyosarcoma: a case report and literature review vol.48, pp.10, 2020, https://doi.org/10.1177/0300060520942107
  20. Focused Ultrasound (FUS) for Chronic Pain Management: Approved and Potential Applications vol.2021, pp.None, 2011, https://doi.org/10.1155/2021/8438498
  21. Robotic system for magnetic resonance guided focused ultrasound ablation of abdominal cancer vol.17, pp.5, 2021, https://doi.org/10.1002/rcs.2299
  22. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies vol.11, pp.6, 2021, https://doi.org/10.1007/s13346-021-01018-0